Senti Biosciences Holdings, Inc. SNTI
Senti Biosciences Holdings, Inc. (Nasdaq: SNTI) is an oncology drug developer. Its lead program, SENTI-202, is in Phase 1 for Relapsed/refractory hematologic malignancies including acute myeloid leukemia (CD33/FLT3 Logic Gated CAR-NK).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| SENTI-202 | R/R hematologic malignancies incl. AML (open-label Phase 1, US and Australia; Orphan Drug and RMAT designations) | cell therapy | Phase 1 |
| Solid tumor cell therapy program | Solid tumors | cell therapy | Pre-clinical |
| BlueRock partnered regenerative medicine programs | Regenerative medicine cell therapies (partnered; BlueRock option agreement) | cell therapy | Pre-clinical |
| Rett Syndrome program | Rett syndrome (to be retained by public company if merger closes) | gene therapy | Pre-clinical |
| TIL program | Tumor infiltrating lymphocyte therapy (to be retained by public company if merger closes) | cell therapy | Pre-clinical |
Recent results and decisions
- Oct 15, 2026n/a Stockholders approved merger agreement with ST NewCo Limited originally dated July 14, 2026.
approved the Agreement and Plan of Merger, dated as of July 14, 2026, by and among ST NewCo Limited (f/k/a Celadon Partners SPV 35 Limited), Senti Merger Sub, Inc., the Company, Midco, and Senti Biosciences, Inc., and the transactions contemplated by the Merger Agreement
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.